ArticleAmerican journal of cancer research2025
WDR3 drives pancreatic cancer metastasis by enhancing TGF-α mRNA stability through YTHDC1.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a highly aggressive malignancy associated with poor prognosis and early metastasis. However, the molecular mechanisms underlying its invasive behavior remain incompletely understood. Here, we identified WD repeat domain 3 (WDR3) as a key driver of pancreatic cancer cell invasion. WDR3 expression is significantly elevated in liver metastatic lesions and is correlated with disease progression. Functional assays revealed that WDR3 promotes cell migration and invasion by upregulating transforming growth factor-α (TGF-α). Mechanistically, WDR3 interacts with the m6A reader YTH domain-containing protein 1 (YTHDC1) and facilitates its K63-linked ubiquitination, resulting in increased cytoplasmic localization of YTHDC1. This modification enhances the stability of TGF-α mRNA, thereby promoting its expression. Knockdown of either WDR3 or YTHDC1 impairs TGF-α expression and suppresses cancer cell invasiveness, whereas YTHDC1 overexpression restores the metastatic phenotype in WDR3-deficient cells. Our findings reveal a novel WDR3-YTHDC1-TGF-α axis that drives pancreatic cancer progression and suggest that targeting WDR3 may be a promising therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.